FDA officials said Tuesday they have approved more generic versions of an older version of a drug that has been linked to heart attacks and strokes.

The FDA’s decision comes less than a week after it approved another generic version of the drug, Abilify, for use in adults and younger children.

The approval, which was made public on Tuesday, is part of a larger wave of generic approvals of Abilifies, which has led to an increase in prescriptions for the drug among older adults and people with chronic diseases.

The new approvals come after several generic versions, including one approved in December, were approved by the FDA in 2017.

The company behind the generic versions says Abilifications could be available within months.

The drug, called Zyrtec, is marketed under the brand name Abilifen, which stands for Abilified Genes, which is a reference to the Abilife brand of generic medications.

Zyrtecs generic version, which began clinical trials last year, has a smaller molecule called ZY-1, which means “young adult.”

The company said it had received requests from consumers who had already received AbilIFen to switch to ZY1.

The generic versions were approved last month, after several years of development, and they were to be offered through Nov. 15.

“This was an important milestone in our ongoing effort to improve the lives of people who need the most powerful medicine in our healthcare system,” said Dr. David Schatz, the FDA’s director of the Center for Drug Evaluation and Research.

The agency also said it will make an announcement on Nov. 14 about new generic versions that were approved for use by patients with diabetes.

An FDA spokesman said in a statement that the agency has been able to address several safety concerns associated with the generic version that it has approved and that the FDA is now reviewing the results of that review.

The statement did not say how long it would take to make a decision about which generic versions will be offered in the future.

More generic drug approval In January, the U:S.

Food and Drug Administration approved Abilifier, a drug approved by other regulators to treat type 2 diabetes.

The government said that the drug’s combination of a lower-dose drug and an older drug, Zyrtenacin, has fewer side effects than the older generic versions.

The FDA’s announcement Tuesday of more generic Abilifiers comes as other drugmakers, including AstraZeneca and Pfizer, have also begun to make generic versions available for patients with type 2, or chronic, diabetes.

Astra Zeneca announced on Tuesday that it had also begun selling a generic version for people with type 1 diabetes, as did Pfizer on Monday.

In the first quarter of 2018, Astra, Pfizer and Pfizers made sales of Abitamins, Abitox and Abitrax generic versions for use with people with diabetes that also had the older versions in them, according to an analysis by Bloomberg.

AstraZeneca, Pfizers and Pfisers have also made other generic versions since the start of the year for people who have type 2 or chronic disease, including Abilix, Ablox, Abolox and Absilix.

Zyrtec was the first generic version to be approved by an FDA in the United States.

Last month, the agency approved another Abilifi, Ablaix, to treat people with Type 1 diabetes and hypertension.

Follow Michael A. Krauss on Twitter at michael_krauss and Google+.